An integrated platform of genomic assays reveals small-molecule bioactivities

Nature Chemical Biology

Volumn 4, Issue 8, 2008, Pages 498-506

  Hoon, Shawn ^a,b   Smith, Andrew M ^c,d   Wallace, Iain M ^d   Suresh, Sundari ^b   Miranda, Molly ^b   Fung, Eula ^b   Proctor, Michael ^b   Shokat, Kevan M ^e   Zhang, Chao ^e   Davis, Ronald W ^a,b   Giaever, Guri ^c,d   Stonge, Robert P ^b   Nislow, Corey ^c,d  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 NM PP1; ACRIDINE DERIVATIVE; ADENOSINE TRIPHOSPHATE DERIVATIVE; AMSACRINE; CALYCULIN A; CANTHARIDIN; FLUCONAZOLE; LATRUNCULIN A; METHOTREXATE; METHYLMETHANE SULFONATE; MICROCYSTIN LR; NOCODAZOLE; RAPAMYCIN; SULFONIC ACID DERIVATIVE;

ARTICLE; ASSAY; CHEMICAL STRUCTURE; CONTROLLED STUDY; DELETION MUTANT; DRUG ACTIVITY; DRUG POTENTIATION; GENE DOSAGE; GENOMIC ASSAY; GENOTYPE; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STRUCTURE ACTIVITY RELATION; YEAST;

EID: 47649093352     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.100     Document Type: Article

References (50)

1. Giaever, G. et al. Chemogenomic profiling: identifying the functional interactions of small molecules in yeast. Proc. Natl. Acad. Sci. USA 101, 793-798 (2004).
2. Lum, P.Y. et al. Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Cell 116, 121-137 (2004).
3. Lee, W. et al. Genome-wide requirements for resistance to functionally distinct DNA-damaging agents. PLoS Genet. 1, 235-246 (2005).
4. Parsons, A.B. et al. Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast. Cell 126, 611-625 (2006).
5. Rine, J., Hansen, W., Hardeman, E. & Davis, R.W. Targeted selection of recombinant clones through gene dosage effects. Proc. Natl. Acad. Sci. USA 80, 6750-6754 (1983).
6. Luesch, H. et al. A genome-wide overexpression screen in yeast for small-molecule target identification. Chem. Biol. 12, 55-63 (2005).
7. Butcher, R.A. et al. Microarray-based method for monitoring yeast overexpression strains reveals small-molecule targets in TOR pathway. Nat. Chem. Biol. 2, 103-109 (2006).
8. Parsons, A.B. et al. Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways. Nat. Biotechnol. 22, 62-69 (2004).
9. Hughes, T.R. et al. Functional discovery via a compendium of expression profiles. Cell 102, 109-126 (2000).
10. Kung, C. et al. Chemical genomic profiling to identify intracellular targets of a multiplex kinase inhibitor. Proc. Natl. Acad. Sci. USA 102, 3587-3592 (2005).
11. Lamb, J. et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929-1935 (2006).
12. Pierce, S.E. et al. A unique and universal molecular barcode array. Nat. Methods 3, 601-603 (2006).
13. Pierce, S.E., Davis, R.W., Nislow, C. & Giaever, G. Genome-wide analysis of barcoded Saccharomyces cerevisiae gene-deletion mutants in pooled cultures. Nat. Protoc. 2, 2958-2974 (2007).
14. Brenner, C. Chemical genomics in yeast. Genome Biol. 5, 240 (2004).
15. Giaever, G. et al. Genomic profiling of drug sensitivities via induced haploinsufficiency. Nat. Genet. 21, 278-283 (1999).
16. Li, X. et al. Multicopy suppressors for novel antibacterial compounds reveal targets and drug efflux susceptibility. Chem. Biol. 11, 1423-1430 (2004).
17. Breitling, R., Armengaud, P. & Amtmann, A. Vector analysis as a fast and easy method to compare gene expression responses between different experimental backgrounds. BMC Bioinformatics 6, 181 (2005).
18. Myers, C.E., Lippman, M.E., Elliot, H.M. & Chabner, B.A. Competitive protein binding assay for methotrexate. Proc. Natl. Acad. Sci. USA 72, 3683-3686 (1975).
19. Kontoyiannis, D.P., Sagar, N. & Hirschi, K.D. Overexpression of Erg11p by the regulatable GAL1 promoter confers fluconazole resistance in Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 43, 2798-2800 (1999).
20. Zheng, X.F., Florentino, D., Chen, J., Crabtree, G.R. & Schreiber, S.L. TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin. Cell 82, 121-130 (1995).
21. Koltin, Y. et al. Rapamycin sensitivity in Saccharomyces cerevisiae is mediated by a peptidyl-prolyl cis-trans isomerase related to human FK506-binding protein. Mol. Cell. Biol. 11, 1718-1723 (1991).
22. Honkanen, R.E. Cantharidin, another natural toxin that inhibits the activity of serine/ threonine protein phosphatases types 1 and 2A. FEBS Lett. 330, 283-286 (1993).
23. Li, Y.M. & Casida, J.E. Cantharidin-binding protein: identification as protein phosphatase 2A. Proc. Natl. Acad. Sci. USA 89, 11867-11870 (1992).
24. Ishihara, H. et al. Calyculin A and okadaic acid: inhibitors of protein phosphatase activity. Biochem. Biophys. Res. Commun. 159, 871-877 (1989).
25. Fujiki, H. & Suganuma, M. Tumor promotion by inhibitors of protein phosphatases 1 and 2A: the okadaic acid class of compounds. Adv. Cancer Res. 61, 143-194 (1993).
26. MacKintosh, C., Beattie, K.A., Klumpp, S., Cohen, P. & Codd, G.A. Cyanobacterial microcystin-LR is a potent and specific inhibitor of protein phosphatases 1 and 2A from both mammals and higher plants. FEBS Lett. 264, 187-192 (1990).
27. Walsh, E.P., Lamont, D.J., Beattie, K.A. & Stark, M.J. Novel interactions of Saccharomyces cerevisiae type 1 protein phosphatase identified by single-step affinity purification and mass spectrometry. Biochemistry 41, 2409-2420 (2002).
28. Krogan, N.J. et al. High-definition macromolecular composition of yeast RNA-processing complexes. Mol. Cell 13, 225-239 (2004).
29. Andrews, P.D. & Stark, M.J. Type 1 protein phosphatase is required for maintenance of cell wall integrity, morphogenesis and cell cycle progression in Saccharomyces cerevisiae. J. Cell Sci. 113, 507-520 (2000).
30. Baker, S.H., Frederick, D.L., Bloecher, A. & Tatchell, K. Alanine-scanning mutagenesis of protein phosphatase type 1 in the yeast Saccharomyces cerevisiae. Genetics 145, 615-626 (1997).
31. Hsu, J.Y. et al. Mitotic phosphorylation of histone H3 is governed by Ipl1/aurora kinase and Glc7/PP1 phosphatase in budding yeast and nematodes. Cell 102, 279-291 (2000).
32. Bloecher, A. & Tatchell, K. Defects in Saccharomyces cerevisiae protein phosphatase type I activate the spindle/kinetochore checkpoint. Genes Dev. 13, 517-522 (1999).
33. Hillenmeyer, M.E. et al. The chemical genomic portrait of yeast: uncovering a phenotype for all genes. Science 320, 362-365 (2008).
34. Martin, J.L. & McMillan, F.M. SAM (dependent) I AM: the S-adenosylmethionine-dependent methyltransferase fold. Curr. Opin. Struct. Biol. 12, 783-793 (2002).
35. Arnaud, M.B. et al. Sequence resources at the Candida Genome Database. Nucleic Acids Res. 35, D452-D456 (2007).
36. Bliss, C. The toxicity of poisons applied jointly. Ann. Appl. Biol. 26, 585-615 (1939).
37. Lehar, J. et al. Chemical combination effects predict connectivity in biological systems. Mol. Syst. Biol. 3, 80 (2007).
38. Stark, C. et al. BioGRID: a general repository for interaction datasets. Nucleic Acids Res. 34, D535-D539 (2006).
39. Young, D.W. et al. Integrating high-content screening and ligand-target prediction to identify mechanism of action. Nat. Chem. Biol. 4, 59-68 (2008).
40. Baguley, B.C. & Nash, R. Antitumour activity of substituted 9-anilinoacridines-comparison of in vivo and in vitro testing systems. Eur. J. Cancer 17, 671-679 (1981).
41. Nelson, E.M., Tewey, K.M. & Liu, L.F. Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4′-(9-acridinylamino)-methanesulfon-m-anisidide. Proc. Natl. Acad. Sci. USA 81, 1361-1365 (1984).
42. Denny, W.A. et al. Potential antitumor agents. 36. Quantitative relationships between experimental antitumor activity, toxicity, and structure for the general class of 9-anilinoacridine antitumor agents. J. Med. Chem. 25, 276-315 (1982).
43. Terstappen, G.C., Schlupen, C., Raggiaschi, R. & Gaviraghi, G. Target deconvolution strategies in drug discovery. Nat. Rev. Drug Discov. 6, 891-903 (2007).
44. Zimmermann, G.R., Lehar, J. & Keith, C.T. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov. Today 12, 34-42 (2007).
45. Borisy, A.A. et al. Systematic discovery of multicomponent therapeutics. Proc. Natl. Acad. Sci. USA 100, 7977-7982 (2003).
46. Bishop, A.C. et al. A chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature 407, 395-401 (2000).
47. Gietz, R.D., Schiestl, R.H., Willems, A.R. & Woods, R.A. Studies on the transformation of intact yeast cells by the LiAc/SS-DNA/PEG procedure. Yeast 11, 355-360 (1995).
48. Kadosh, D. & Johnson, A.D. Rfg1, a protein related to the Saccharomyces cerevisiae hypoxic regulator Rox1, controls filamentous growth and virulence in Candida albicans. Mol. Cell. Biol. 21, 2496-2505 (2001).
49. Lan, C.Y. et al. Metabolic specialization associated with phenotypic switching in Candida albicans. Proc. Natl. Acad. Sci. USA 99, 14907-14912 (2002).
50. Breitling, R., Armengaud, P., Amtmann, A. & Herzyk, P. Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett. 573, 83-92 (2004).